Research organisation · Alderley Park
Quantum computing work at the Alderley Park drug discovery Catapult centres on QuPharma, a SEEQC-led Innovate UK project that ran from March 2022 to March 2025. The consortium paired a SEEQC quantum computer with a classical supercomputer to model drug properties, and the Catapult's job, alongside Merck and the University of Oxford, was to find the stages of drug discovery where a quantum computer could actually help. Gateway to Research shows it received a full grant of £243,588.
Medicines Discovery Catapult, based in Alderley Park, is a research organisation. It appears as a partner in QuPharma.
Sources: Gateway to Research: Quantum Enhanced Computing Platform for Pharmaceutical R&D, QuPharma (10005792) · STFC Hartree Centre: £50m funding for UK quantum computing projects with industry (November 2021) · Medicines Discovery Catapult
QuPharma
A SEEQC-led consortium linking a quantum computer with a classical supercomputer to model drug properties.
Role: Partner
Themes: Computing, Biomedical and health
Recent articles from Quantum Zeitgeist that mention Medicines Discovery Catapult.
SEEQC, the digital quantum computing firm from New York, and BASF (Badische Anilin und Soda Fabrik), the world’s largest chemical corporation based in Germany, announced their collaboration to accelerate the investigation of the use of quantum computing in chemical reactions. This study will look pr
Image © Quantum Zeitgeist
The latest round of the UK government’s Commercialising Quantum Technologies challenge awarded Riverlane a total of £2.5 million for its projects. Starting in 2022, a total of four initiatives will engage with hardware and enterprise partners to address the significance of the scientific and enginee
Image © Quantum Zeitgeist
News from Quantum Zeitgeist.
Logos and names are trademarks of their respective owners, used to identify them. No endorsement implied.
